Antibody reactivities in HSCT patient plasma against skin keratinocyte antigens. Antibody reactivities in patient plasma were tested against membrane antigens from the skin keratinocyte cell line (CCD1106). (A) Antibody reactivities from individual patients who did not develop cGVHD after HSCT (n = 19). (B) Antibody reactivities from individual patients who developed cGVHD during the 3 years after HSCT (n = 30). (C) The mean fluorescence intensity from cGVHD group and No cGVHD group. (D) The mean fluorescence intensity of the cGVHD group after the time points of all patients within the group were synchronized to the time of cGVHD clinical onset. P = .03.